Eintrag weiter verarbeiten
IFNβ1 secreted by breast cancer cells undergoing chemotherapy reprograms stromal fibroblasts to support tumour growth after treatment
Gespeichert in:
| Zeitschriftentitel: | Molecular Oncology |
|---|---|
| Personen und Körperschaften: | , , , , , , |
| In: | Molecular Oncology, 15, 2021, 5, S. 1308-1329 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Wiley
|
| Schlagwörter: |
| author_facet |
Maia, Ana Gu, Zuguang Koch, André Berdiel‐Acer, Mireia Will, Rainer Schlesner, Matthias Wiemann, Stefan Maia, Ana Gu, Zuguang Koch, André Berdiel‐Acer, Mireia Will, Rainer Schlesner, Matthias Wiemann, Stefan |
|---|---|
| author |
Maia, Ana Gu, Zuguang Koch, André Berdiel‐Acer, Mireia Will, Rainer Schlesner, Matthias Wiemann, Stefan |
| spellingShingle |
Maia, Ana Gu, Zuguang Koch, André Berdiel‐Acer, Mireia Will, Rainer Schlesner, Matthias Wiemann, Stefan Molecular Oncology IFNβ1 secreted by breast cancer cells undergoing chemotherapy reprograms stromal fibroblasts to support tumour growth after treatment Cancer Research Genetics Molecular Medicine General Medicine Oncology |
| author_sort |
maia, ana |
| spelling |
Maia, Ana Gu, Zuguang Koch, André Berdiel‐Acer, Mireia Will, Rainer Schlesner, Matthias Wiemann, Stefan 1574-7891 1878-0261 Wiley Cancer Research Genetics Molecular Medicine General Medicine Oncology http://dx.doi.org/10.1002/1878-0261.12905 <jats:p>Chemotherapy (CTX) remains the standard of care for most aggressive tumours, including breast cancer (BC). In BC chemotherapeutic regimens, the maximum tolerated dose of cytotoxic drugs is administered at regular intervals, and cancer cells can re‐grow or adapt during the resting periods between cycles. The impact of the tumour microenvironment on the fate of cancer cells after CTX remains poorly understood. Here, we show that paracrine signalling from CTX‐treated cancer cells to stromal fibroblasts can drive cancer cell recovery after cytotoxic drug withdrawal. Interferon β1 (IFNβ1) secreted by cancer cells following treatment with high doses of CTX instigates the acquisition of an anti‐viral state in stromal fibroblasts. This state is associated with an expression pattern here referred to as interferon signature (IFNS), which encompasses several interferon‐stimulated genes (ISGs), including numerous pro‐inflammatory cytokine genes. This crosstalk is an important driver of the expansion of BC cells after CTX, and IFNβ1 blockade in tumour cells abrogated their fibroblast‐dependent recovery potential. Analysis of human breast carcinomas supported a link between CTX‐induced IFNS in tumour stroma and poor response to CTX treatment. First, IFNβ1 expression in human breast carcinomas was found to inversely correlate with recurrence free survival (RFS). Second, using laser capture microdissection data sets, we show a higher expression of IFNS in the stromal tumour compartment compared to the epithelial one and this signature was found to be more prominent in more aggressive subtypes of BC (basal‐like), pointing to a pro‐tumorigenic role of this signature. Moreover, IFNS was associated with higher recurrence rates and a worse outcome in BC patients. Our study unravels a novel form of paracrine communication between cancer cells and fibroblasts that ultimately results in CTX resistance. Targeting this axis has the potential to improve CTX outcomes in patients with BC.</jats:p> IFNβ1 secreted by breast cancer cells undergoing chemotherapy reprograms stromal fibroblasts to support tumour growth after treatment Molecular Oncology |
| doi_str_mv |
10.1002/1878-0261.12905 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin Biologie |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi8xODc4LTAyNjEuMTI5MDU |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi8xODc4LTAyNjEuMTI5MDU |
| institution |
DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-D161 DE-Zwi2 DE-Gla1 DE-Zi4 |
| imprint |
Wiley, 2021 |
| imprint_str_mv |
Wiley, 2021 |
| issn |
1574-7891 1878-0261 |
| issn_str_mv |
1574-7891 1878-0261 |
| language |
English |
| mega_collection |
Wiley (CrossRef) |
| match_str |
maia2021ifnb1secretedbybreastcancercellsundergoingchemotherapyreprogramsstromalfibroblaststosupporttumourgrowthaftertreatment |
| publishDateSort |
2021 |
| publisher |
Wiley |
| recordtype |
ai |
| record_format |
ai |
| series |
Molecular Oncology |
| source_id |
49 |
| title |
IFNβ1 secreted by breast cancer cells undergoing chemotherapy reprograms stromal fibroblasts to support tumour growth after treatment |
| title_unstemmed |
IFNβ1 secreted by breast cancer cells undergoing chemotherapy reprograms stromal fibroblasts to support tumour growth after treatment |
| title_full |
IFNβ1 secreted by breast cancer cells undergoing chemotherapy reprograms stromal fibroblasts to support tumour growth after treatment |
| title_fullStr |
IFNβ1 secreted by breast cancer cells undergoing chemotherapy reprograms stromal fibroblasts to support tumour growth after treatment |
| title_full_unstemmed |
IFNβ1 secreted by breast cancer cells undergoing chemotherapy reprograms stromal fibroblasts to support tumour growth after treatment |
| title_short |
IFNβ1 secreted by breast cancer cells undergoing chemotherapy reprograms stromal fibroblasts to support tumour growth after treatment |
| title_sort |
ifnβ1 secreted by breast cancer cells undergoing chemotherapy reprograms stromal fibroblasts to support tumour growth after treatment |
| topic |
Cancer Research Genetics Molecular Medicine General Medicine Oncology |
| url |
http://dx.doi.org/10.1002/1878-0261.12905 |
| publishDate |
2021 |
| physical |
1308-1329 |
| description |
<jats:p>Chemotherapy (CTX) remains the standard of care for most aggressive tumours, including breast cancer (BC). In BC chemotherapeutic regimens, the maximum tolerated dose of cytotoxic drugs is administered at regular intervals, and cancer cells can re‐grow or adapt during the resting periods between cycles. The impact of the tumour microenvironment on the fate of cancer cells after CTX remains poorly understood. Here, we show that paracrine signalling from CTX‐treated cancer cells to stromal fibroblasts can drive cancer cell recovery after cytotoxic drug withdrawal. Interferon β1 (IFNβ1) secreted by cancer cells following treatment with high doses of CTX instigates the acquisition of an anti‐viral state in stromal fibroblasts. This state is associated with an expression pattern here referred to as interferon signature (IFNS), which encompasses several interferon‐stimulated genes (ISGs), including numerous pro‐inflammatory cytokine genes. This crosstalk is an important driver of the expansion of BC cells after CTX, and IFNβ1 blockade in tumour cells abrogated their fibroblast‐dependent recovery potential. Analysis of human breast carcinomas supported a link between CTX‐induced IFNS in tumour stroma and poor response to CTX treatment. First, IFNβ1 expression in human breast carcinomas was found to inversely correlate with recurrence free survival (RFS). Second, using laser capture microdissection data sets, we show a higher expression of IFNS in the stromal tumour compartment compared to the epithelial one and this signature was found to be more prominent in more aggressive subtypes of BC (basal‐like), pointing to a pro‐tumorigenic role of this signature. Moreover, IFNS was associated with higher recurrence rates and a worse outcome in BC patients. Our study unravels a novel form of paracrine communication between cancer cells and fibroblasts that ultimately results in CTX resistance. Targeting this axis has the potential to improve CTX outcomes in patients with BC.</jats:p> |
| container_issue |
5 |
| container_start_page |
1308 |
| container_title |
Molecular Oncology |
| container_volume |
15 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792348333274038278 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T18:09:30.727Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=IFN%CE%B21+secreted+by+breast+cancer+cells+undergoing+chemotherapy+reprograms+stromal+fibroblasts+to+support+tumour+growth+after+treatment&rft.date=2021-05-01&genre=article&issn=1878-0261&volume=15&issue=5&spage=1308&epage=1329&pages=1308-1329&jtitle=Molecular+Oncology&atitle=IFN%CE%B21+secreted+by+breast+cancer+cells+undergoing+chemotherapy+reprograms+stromal+fibroblasts+to+support+tumour+growth+after+treatment&aulast=Wiemann&aufirst=Stefan&rft_id=info%3Adoi%2F10.1002%2F1878-0261.12905&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792348333274038278 |
| author | Maia, Ana, Gu, Zuguang, Koch, André, Berdiel‐Acer, Mireia, Will, Rainer, Schlesner, Matthias, Wiemann, Stefan |
| author_facet | Maia, Ana, Gu, Zuguang, Koch, André, Berdiel‐Acer, Mireia, Will, Rainer, Schlesner, Matthias, Wiemann, Stefan, Maia, Ana, Gu, Zuguang, Koch, André, Berdiel‐Acer, Mireia, Will, Rainer, Schlesner, Matthias, Wiemann, Stefan |
| author_sort | maia, ana |
| container_issue | 5 |
| container_start_page | 1308 |
| container_title | Molecular Oncology |
| container_volume | 15 |
| description | <jats:p>Chemotherapy (CTX) remains the standard of care for most aggressive tumours, including breast cancer (BC). In BC chemotherapeutic regimens, the maximum tolerated dose of cytotoxic drugs is administered at regular intervals, and cancer cells can re‐grow or adapt during the resting periods between cycles. The impact of the tumour microenvironment on the fate of cancer cells after CTX remains poorly understood. Here, we show that paracrine signalling from CTX‐treated cancer cells to stromal fibroblasts can drive cancer cell recovery after cytotoxic drug withdrawal. Interferon β1 (IFNβ1) secreted by cancer cells following treatment with high doses of CTX instigates the acquisition of an anti‐viral state in stromal fibroblasts. This state is associated with an expression pattern here referred to as interferon signature (IFNS), which encompasses several interferon‐stimulated genes (ISGs), including numerous pro‐inflammatory cytokine genes. This crosstalk is an important driver of the expansion of BC cells after CTX, and IFNβ1 blockade in tumour cells abrogated their fibroblast‐dependent recovery potential. Analysis of human breast carcinomas supported a link between CTX‐induced IFNS in tumour stroma and poor response to CTX treatment. First, IFNβ1 expression in human breast carcinomas was found to inversely correlate with recurrence free survival (RFS). Second, using laser capture microdissection data sets, we show a higher expression of IFNS in the stromal tumour compartment compared to the epithelial one and this signature was found to be more prominent in more aggressive subtypes of BC (basal‐like), pointing to a pro‐tumorigenic role of this signature. Moreover, IFNS was associated with higher recurrence rates and a worse outcome in BC patients. Our study unravels a novel form of paracrine communication between cancer cells and fibroblasts that ultimately results in CTX resistance. Targeting this axis has the potential to improve CTX outcomes in patients with BC.</jats:p> |
| doi_str_mv | 10.1002/1878-0261.12905 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin, Biologie |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi8xODc4LTAyNjEuMTI5MDU |
| imprint | Wiley, 2021 |
| imprint_str_mv | Wiley, 2021 |
| institution | DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-D161, DE-Zwi2, DE-Gla1, DE-Zi4 |
| issn | 1574-7891, 1878-0261 |
| issn_str_mv | 1574-7891, 1878-0261 |
| language | English |
| last_indexed | 2024-03-01T18:09:30.727Z |
| match_str | maia2021ifnb1secretedbybreastcancercellsundergoingchemotherapyreprogramsstromalfibroblaststosupporttumourgrowthaftertreatment |
| mega_collection | Wiley (CrossRef) |
| physical | 1308-1329 |
| publishDate | 2021 |
| publishDateSort | 2021 |
| publisher | Wiley |
| record_format | ai |
| recordtype | ai |
| series | Molecular Oncology |
| source_id | 49 |
| spelling | Maia, Ana Gu, Zuguang Koch, André Berdiel‐Acer, Mireia Will, Rainer Schlesner, Matthias Wiemann, Stefan 1574-7891 1878-0261 Wiley Cancer Research Genetics Molecular Medicine General Medicine Oncology http://dx.doi.org/10.1002/1878-0261.12905 <jats:p>Chemotherapy (CTX) remains the standard of care for most aggressive tumours, including breast cancer (BC). In BC chemotherapeutic regimens, the maximum tolerated dose of cytotoxic drugs is administered at regular intervals, and cancer cells can re‐grow or adapt during the resting periods between cycles. The impact of the tumour microenvironment on the fate of cancer cells after CTX remains poorly understood. Here, we show that paracrine signalling from CTX‐treated cancer cells to stromal fibroblasts can drive cancer cell recovery after cytotoxic drug withdrawal. Interferon β1 (IFNβ1) secreted by cancer cells following treatment with high doses of CTX instigates the acquisition of an anti‐viral state in stromal fibroblasts. This state is associated with an expression pattern here referred to as interferon signature (IFNS), which encompasses several interferon‐stimulated genes (ISGs), including numerous pro‐inflammatory cytokine genes. This crosstalk is an important driver of the expansion of BC cells after CTX, and IFNβ1 blockade in tumour cells abrogated their fibroblast‐dependent recovery potential. Analysis of human breast carcinomas supported a link between CTX‐induced IFNS in tumour stroma and poor response to CTX treatment. First, IFNβ1 expression in human breast carcinomas was found to inversely correlate with recurrence free survival (RFS). Second, using laser capture microdissection data sets, we show a higher expression of IFNS in the stromal tumour compartment compared to the epithelial one and this signature was found to be more prominent in more aggressive subtypes of BC (basal‐like), pointing to a pro‐tumorigenic role of this signature. Moreover, IFNS was associated with higher recurrence rates and a worse outcome in BC patients. Our study unravels a novel form of paracrine communication between cancer cells and fibroblasts that ultimately results in CTX resistance. Targeting this axis has the potential to improve CTX outcomes in patients with BC.</jats:p> IFNβ1 secreted by breast cancer cells undergoing chemotherapy reprograms stromal fibroblasts to support tumour growth after treatment Molecular Oncology |
| spellingShingle | Maia, Ana, Gu, Zuguang, Koch, André, Berdiel‐Acer, Mireia, Will, Rainer, Schlesner, Matthias, Wiemann, Stefan, Molecular Oncology, IFNβ1 secreted by breast cancer cells undergoing chemotherapy reprograms stromal fibroblasts to support tumour growth after treatment, Cancer Research, Genetics, Molecular Medicine, General Medicine, Oncology |
| title | IFNβ1 secreted by breast cancer cells undergoing chemotherapy reprograms stromal fibroblasts to support tumour growth after treatment |
| title_full | IFNβ1 secreted by breast cancer cells undergoing chemotherapy reprograms stromal fibroblasts to support tumour growth after treatment |
| title_fullStr | IFNβ1 secreted by breast cancer cells undergoing chemotherapy reprograms stromal fibroblasts to support tumour growth after treatment |
| title_full_unstemmed | IFNβ1 secreted by breast cancer cells undergoing chemotherapy reprograms stromal fibroblasts to support tumour growth after treatment |
| title_short | IFNβ1 secreted by breast cancer cells undergoing chemotherapy reprograms stromal fibroblasts to support tumour growth after treatment |
| title_sort | ifnβ1 secreted by breast cancer cells undergoing chemotherapy reprograms stromal fibroblasts to support tumour growth after treatment |
| title_unstemmed | IFNβ1 secreted by breast cancer cells undergoing chemotherapy reprograms stromal fibroblasts to support tumour growth after treatment |
| topic | Cancer Research, Genetics, Molecular Medicine, General Medicine, Oncology |
| url | http://dx.doi.org/10.1002/1878-0261.12905 |